Synmosa Biopharma
Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches, develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand in Taiwan. The company offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company also provides its products in various forms, suc… Read more
Synmosa Biopharma (4114) - Total Assets
Latest total assets as of September 2025: NT$14.07 Billion TWD
Based on the latest financial reports, Synmosa Biopharma (4114) holds total assets worth NT$14.07 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Synmosa Biopharma - Total Assets Trend (2015–2024)
This chart illustrates how Synmosa Biopharma’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Synmosa Biopharma - Asset Composition Analysis
Current Asset Composition (December 2024)
Synmosa Biopharma's total assets of NT$14.07 Billion consist of 40.8% current assets and 59.2% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 9.6% |
| Accounts Receivable | NT$1.16 Billion | 9.4% |
| Inventory | NT$1.71 Billion | 13.9% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$449.22 Million | 3.7% |
| Goodwill | NT$62.29 Million | 0.5% |
Asset Composition Trend (2015–2024)
This chart illustrates how Synmosa Biopharma's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Synmosa Biopharma's current assets represent 40.8% of total assets in 2024, an increase from 25.9% in 2015.
- Cash Position: Cash and equivalents constituted 9.6% of total assets in 2024, up from 5.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 4.0% in 2015.
- Asset Diversification: The largest asset category is inventory at 13.9% of total assets.
Synmosa Biopharma Competitors by Total Assets
Key competitors of Synmosa Biopharma based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Synmosa Biopharma - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Synmosa Biopharma generates 0.45x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Synmosa Biopharma generates $5.56 in net profit.
Synmosa Biopharma - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.45 | 2.38 | 1.91 |
| Quick Ratio | 1.57 | 1.54 | 1.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$3.47 Billion | NT$ 2.84 Billion | NT$ 1.42 Billion |
Synmosa Biopharma - Advanced Valuation Insights
This section examines the relationship between Synmosa Biopharma's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.79 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 4.9% |
| Total Assets | NT$12.30 Billion |
| Market Capitalization | $374.66 Million USD |
Valuation Analysis
Below Book Valuation: The market values Synmosa Biopharma's assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Synmosa Biopharma's assets grew by 4.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Synmosa Biopharma (2015–2024)
The table below shows the annual total assets of Synmosa Biopharma from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$12.30 Billion | +4.91% |
| 2023-12-31 | NT$11.73 Billion | +4.70% |
| 2022-12-31 | NT$11.20 Billion | +8.59% |
| 2021-12-31 | NT$10.32 Billion | -0.58% |
| 2020-12-31 | NT$10.38 Billion | +18.87% |
| 2019-12-31 | NT$8.73 Billion | +15.71% |
| 2018-12-31 | NT$7.54 Billion | +0.55% |
| 2017-12-31 | NT$7.50 Billion | +10.52% |
| 2016-12-31 | NT$6.79 Billion | +47.83% |
| 2015-12-31 | NT$4.59 Billion | -- |